Financial Results for the First Quarter
of Fiscal Year Ending March 31, 2027 (FY2026)

from the beginning

Financial Results for the First Quarter of Fiscal Year Ending March 31, 2027 (FY2026)

• Forward-Looking Statements and Use of Document

• Highlights

• P&L, FCF

• OP Variance Analysis: Growth due to strong sales and a tariff refund

• C&V: TIS led growth, TN and TCV also performed well

• TMCS: HCS and PS drove revenue and profit growth

• TBCT: Strong global demand for blood collection products; Rika also contributed

• OT: Rapid Revenue Growth Driven by Expanding Liver Transplant Market

• Revenue by Region: Growth led by Americas, Europe, and Asia

Revision of FY26 Guidance

• Revision of FY26 Guidance

• Revision of FY26 Guidance by Company

Reference

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and Amortization, R&D Expenses

• Free Cash Flow

• Cash Flow

• Foreign Exchange Sensitivity

@